1. Home
  2. CADL vs GEVO Comparison

CADL vs GEVO Comparison

Compare CADL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$6.26

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.78

Market Cap

468.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
GEVO
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
357.4M
468.8M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
CADL
GEVO
Price
$6.26
$1.78
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$19.00
$6.58
AVG Volume (30 Days)
1.7M
5.0M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.62
58.82
EPS
N/A
N/A
Revenue
$125,000.00
$711,000.00
Revenue This Year
N/A
$19.44
Revenue Next Year
N/A
$5.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.34
$1.00
52 Week High
$7.66
$2.97

Technical Indicators

Market Signals
Indicator
CADL
GEVO
Relative Strength Index (RSI) 57.38 37.89
Support Level $5.42 $1.72
Resistance Level $6.41 $1.89
Average True Range (ATR) 0.48 0.11
MACD 0.14 -0.02
Stochastic Oscillator 51.30 37.23

Price Performance

Historical Comparison
CADL
GEVO

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

Share on Social Networks: